European Commission Approves Clovis’ Rubraca for Recurrent Ovarian Cancer
News
The European Commission recently authorized Rubraca (rucaparib) for the treatment for women with recurrent BRCA-mutant ovarian cancer with relapsed or progressive disease. The recent approval is for the maintenance treatment of recurrent ... Read more